FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096875998> ?p ?o ?g. }

• W2096875998 endingPage "193" @default.
• W2096875998 startingPage "185" @default.
• W2096875998 abstract "SUMMARY The effect of dose and schedule of continuous i.v. rIL-2 infusions on leucocyte subset counts, activation status of CD56+CD3- natural killer (NK) and CD3+ T lymphocytes, and cytolytic activities of peripheral blood mononuclear cells (PBMC) was studied. A single 4-day course of rIL-2 in escalating doses (0.9-11.5 × 106 U/m2 per day) was given to 18 patients with various types of metastatic cancer. The serum IL-2 concentration during rIL-2 Iherapy ranged between 23 and 64 U/ ml and was proportional to ihe administered rIL-2 dose, as was the rebound lympbocytosis following therapy. Before therapy, the CD56+CD3- NK cells expressed low levels of the p75 chain of the IL-2 receptor (IL-2R) and virtually no IL-2R(p55). Most CD3+ T cells were IL-2R(p55,p75). Between 2 and 4 days following therapy, i.e. at the time of lymphocytosis, the percentage of CD56+, CD3 NK cells among tbe lymphocytes had increased proportional to tbe administered rIL-2dose. The levels of IL-2R(p75) expression by the CD56+, CD3 NK cells had increased. The percentages of CD3+ T cells expressing IL-2R(p55). H LA-DR and CD45RO had increased proportional to the administered rIL-2 dose. The level of lymphokine- activated killer (LAK) activity against Daudi cells was also positively correlated with rIL-2 dose. Subsequently, seven patients received 4-weekly cycles of rIL-2 (2.9-4.4 × 106 U/m2 per day) during 4 consecutive weeks. This schedule led to marked increments in lymphocyte and eosinopbil counts, and to increased cytolytic activities compared with pretreatment. We conclude that CD56+, CD3- NK and CD3+ T cells are activated differentially by continuous i.v. rIL-2 proportional to dose and duration of treatment." @default.
• W2096875998 created "2016-06-24" @default.
• W2096875998 creator A5010157510 @default.
• W2096875998 creator A5021668907 @default.
• W2096875998 creator A5037696756 @default.
• W2096875998 creator A5040016234 @default.
• W2096875998 creator A5068667098 @default.
• W2096875998 creator A5070370737 @default.
• W2096875998 creator A5083953243 @default.
• W2096875998 date "1993-05-01" @default.
• W2096875998 modified "2023-10-17" @default.
• W2096875998 title "Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2" @default.
• W2096875998 cites W1496485733 @default.
• W2096875998 cites W1504038693 @default.
• W2096875998 cites W1592924232 @default.
• W2096875998 cites W1643040145 @default.
• W2096875998 cites W1654999679 @default.
• W2096875998 cites W1769520442 @default.
• W2096875998 cites W1966475570 @default.
• W2096875998 cites W1970687999 @default.
• W2096875998 cites W1975568557 @default.
• W2096875998 cites W1981547010 @default.
• W2096875998 cites W1984445688 @default.
• W2096875998 cites W2004421209 @default.
• W2096875998 cites W2007324489 @default.
• W2096875998 cites W201918455 @default.
• W2096875998 cites W2060291012 @default.
• W2096875998 cites W2071191803 @default.
• W2096875998 cites W2071600835 @default.
• W2096875998 cites W2077055002 @default.
• W2096875998 cites W2087117578 @default.
• W2096875998 cites W2102016301 @default.
• W2096875998 cites W2104066024 @default.
• W2096875998 cites W211185702 @default.
• W2096875998 cites W2117670724 @default.
• W2096875998 cites W2123276910 @default.
• W2096875998 cites W2132363654 @default.
• W2096875998 cites W2136445642 @default.
• W2096875998 cites W2140202337 @default.
• W2096875998 cites W2162588324 @default.
• W2096875998 cites W2168025297 @default.
• W2096875998 cites W2179970611 @default.
• W2096875998 cites W2232513579 @default.
• W2096875998 cites W2326245275 @default.
• W2096875998 cites W2402462694 @default.
• W2096875998 cites W1982032535 @default.
• W2096875998 doi "https://doi.org/10.1111/j.1365-2249.1993.tb03378.x" @default.
• W2096875998 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1554808" @default.
• W2096875998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8485906" @default.
• W2096875998 hasPublicationYear "1993" @default.
• W2096875998 type Work @default.
• W2096875998 sameAs 2096875998 @default.
• W2096875998 citedByCount "12" @default.
• W2096875998 countsByYear W20968759982018 @default.
• W2096875998 countsByYear W20968759982019 @default.
• W2096875998 countsByYear W20968759982020 @default.
• W2096875998 crossrefType "journal-article" @default.
• W2096875998 hasAuthorship W2096875998A5010157510 @default.
• W2096875998 hasAuthorship W2096875998A5021668907 @default.
• W2096875998 hasAuthorship W2096875998A5037696756 @default.
• W2096875998 hasAuthorship W2096875998A5040016234 @default.
• W2096875998 hasAuthorship W2096875998A5068667098 @default.
• W2096875998 hasAuthorship W2096875998A5070370737 @default.
• W2096875998 hasAuthorship W2096875998A5083953243 @default.
• W2096875998 hasBestOaLocation W20968759982 @default.
• W2096875998 hasConcept C114684123 @default.
• W2096875998 hasConcept C126322002 @default.
• W2096875998 hasConcept C137061746 @default.
• W2096875998 hasConcept C154317977 @default.
• W2096875998 hasConcept C167672396 @default.
• W2096875998 hasConcept C202751555 @default.
• W2096875998 hasConcept C203014093 @default.
• W2096875998 hasConcept C2777371288 @default.
• W2096875998 hasConcept C2778102761 @default.
• W2096875998 hasConcept C2780126324 @default.
• W2096875998 hasConcept C2908885563 @default.
• W2096875998 hasConcept C49382859 @default.
• W2096875998 hasConcept C55493867 @default.
• W2096875998 hasConcept C71924100 @default.
• W2096875998 hasConcept C86803240 @default.
• W2096875998 hasConcept C8891405 @default.
• W2096875998 hasConceptScore W2096875998C114684123 @default.
• W2096875998 hasConceptScore W2096875998C126322002 @default.
• W2096875998 hasConceptScore W2096875998C137061746 @default.
• W2096875998 hasConceptScore W2096875998C154317977 @default.
• W2096875998 hasConceptScore W2096875998C167672396 @default.
• W2096875998 hasConceptScore W2096875998C202751555 @default.
• W2096875998 hasConceptScore W2096875998C203014093 @default.
• W2096875998 hasConceptScore W2096875998C2777371288 @default.
• W2096875998 hasConceptScore W2096875998C2778102761 @default.
• W2096875998 hasConceptScore W2096875998C2780126324 @default.
• W2096875998 hasConceptScore W2096875998C2908885563 @default.
• W2096875998 hasConceptScore W2096875998C49382859 @default.
• W2096875998 hasConceptScore W2096875998C55493867 @default.
• W2096875998 hasConceptScore W2096875998C71924100 @default.
• W2096875998 hasConceptScore W2096875998C86803240 @default.
• W2096875998 hasConceptScore W2096875998C8891405 @default.
• W2096875998 hasIssue "2" @default.

• next